Drug Trial Radar · NCT02418455
Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
Last checked: Nov 20, 2026Latest source record: Oct 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jul 21, 2015
Primary completion
Mar 26, 2019
Study completion Mar 26, 2019
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 day, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective was to evaluate the effect of UX003 treatment in pediatric MPS VII participants less than 5 years of age on safety, tolerability, and efficacy as determined by the reduction of urinary glycosaminoglycans (uGAG) excretion.
Conditions
- Sly Syndrome
- MPS VII
- Mucopolysaccharidosis
- Mucopolysaccharidosis VII
Interventions
UX003Drug
solution for intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in uGAG Excretion (LC-MS/MS-DS) at Week 48Time frame: Baseline (Week 0), Week 48
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuations Due to TEAEsTime frame: From first dose of study drug until 30 days after the last dose of study drug. Mean (SD) treatment duration was 98.11 (29.02) weeks
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Children's National Health System
Washington D.C., District of Columbia
New York University Langone Medical Center
New York, New York
University of Utah Hospital
Salt Lake City, Utah
Centro Hospitalar do Porto
Porto, Portugal
Hospital Universitario Virgen Del Rocio
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.